A new treatment for diffuse large B-cell lymphoma
Official title: A Next-Generation Nucleoside Prodrug for Diffuse Large B-Cell Lymphoma
Funded at Thomas Jefferson University · NIH-11001979 · Data updated 2026-11-12
This study is testing a new treatment for diffuse large B-cell lymphoma (DLBCL) using a special compound that has shown promise in lab tests, and it's designed for patients who haven't had success with current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | December 18, 2023 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $623,596 |
| NIH project number | 5R01CA279364-02 |
| Project ID | NIH-11001979 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults and children diagnosed with diffuse large B-cell lymphoma, especially those who have not responded to standard treatments.
✕Less likely to help
Patients with other types of cancers or those who do not have diffuse large B-cell lymphoma may not benefit from this research.
What this research studies
This research focuses on developing a novel nucleoside prodrug aimed at treating diffuse large B-cell lymphoma (DLBCL), a common type of blood cancer. The approach involves using a compound called 4’-ethynyl-deoxycytidine (EdC), which has shown high effectiveness in pre-clinical tests against DLBCL cells. By inducing replicative stress and inhibiting DNA damage response, EdC aims to provide a new therapeutic option for patients who have not responded to existing treatments. The research includes extensive screening of cancer cell lines to identify the most promising candidates for further development.
Why it matters
Potential benefit: If successful, this research could offer a new, effective treatment option for patients with diffuse large B-cell lymphoma, particularly those who have relapsed or are resistant to current therapies.
How similar studies have gone: Previous research has shown success with similar nucleoside analogs in treating hematological cancers, indicating a promising avenue for this novel approach.
Where this research is happening
-
Thomas Jefferson University
Philadelphia, United States Active
Researchers
- Principal investigator: Pomerantz, Richard T — Thomas Jefferson University
- Study coordinator: Pomerantz, Richard T
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.